This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Radiotherapy for Malignant Astrocytomas in the Elderly

This study has been completed.
Information provided by:
Assistance Publique - Hôpitaux de Paris Identifier:
First received: January 31, 2007
Last updated: NA
Last verified: January 2007
History: No changes posted
A randomized trial comparing radiotherapy with supportive care in patients aged 70 years or older with newly diagnosed, histologically confirmed anaplastic astrocytoma or glioblastoma, and a Karnofsky performance status > 70.

Condition Intervention Phase
Primary Brain Tumor Anaplastic Astrocytoma Glioblastoma Multiforme Drug: Radiotherapy Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Survival

Secondary Outcome Measures:
  • Progression free survival
  • Quality of life
  • Cognitive functions

Study Start Date: February 2001

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Glioblastoma and anaplastic astrocytoma, supratentorial, histologically confirmed
  • Brain CT scan or MRI within 28 days before surgery
  • Age: 70 years or older
  • Karnofsky performance status, 70 or more.
  • Life expectancy over 12 weeks
  • Informed consent

Exclusion Criteria:

  • Brain radiotherapy
  • Chemotherapy
  • Severe systemic disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00430911

Hôpital de la Salpêtrière
Paris, Ile de France, France, 75013
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Principal Investigator: jean-yves Delattre, MD Assistance Publique - Hôpitaux de Paris
Principal Investigator: Florence Keime-Guibert, MD Assitance Publique-Hôpitaux de Paris
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00430911     History of Changes
Other Study ID Numbers: PHRC, P000502 AOM 98071
Study First Received: January 31, 2007
Last Updated: January 31, 2007

Keywords provided by Assistance Publique - Hôpitaux de Paris:
malignant gliomas

Additional relevant MeSH terms:
Brain Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on September 19, 2017